Expertise in
12
conditions

Dr. Asher A. Chanan-Khan

Hematology
Mayo Clinic Hospital In Florida
4500 San Pablo Rd S, 
Jacksonville, FL 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
12
conditions
Mayo Clinic Hospital In Florida
4500 San Pablo Rd S, 
Jacksonville, FL 

Overview

Asher Chanan-Khan is a Hematologist practicing medicine in Jacksonville, Florida.

Dr. Chanan-Khan is highly rated in 12 conditions, according to our data. His clinical expertise encompasses Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma, Waldenstrom Macroglobulinemia, Bone Marrow Aspiration, and Bone Marrow Transplant.

He is actively involved in clinical research, co-authoring 153 peer reviewed articles and participating in 12 clinical trials.

Specialties

Hematology

Licenses

Internal Medicine in NY

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO

Locations

Mayo Clinic Hospital In Florida
4500 San Pablo Rd S, Jacksonville, FL 32224

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

Randomized Phase 2 Study Comparing Acalabrutinib to Acalabrutinib and Obinutuzumab in the Treatment of Patients With Early-Stage Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Who Are at High Risk of Disease Progression
Randomized Phase 2 Study Comparing Acalabrutinib to Acalabrutinib and Obinutuzumab in the Treatment of Patients With Early-Stage Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Who Are at High Risk of Disease Progression
Enrollment Status: Recruiting
Publish Date: June 24, 2026
Intervention Type: Other, Biological, Drug
Study Drugs: Acalabrutinib, Obinutuzumab
Study Phase: Phase 2
Phase II Study of Ibrutinib in Combination With Ixazomib in Patients With Waldenström Macroglobulinemia
Phase II Study of Ibrutinib in Combination With Ixazomib in Patients With Waldenström Macroglobulinemia
Enrollment Status: Terminated
Publish Date: May 05, 2026
Intervention Type: Drug, Other
Study Drugs: Ibrutinib, Ixazomib Citrate
Study Phase: Phase 2
Minimal Residual Disease Eradication With Ibrutinib Therapy (MERIT) in Patients With Chronic Lymphocytic Leukemia After Frontline Therapy
Minimal Residual Disease Eradication With Ibrutinib Therapy (MERIT) in Patients With Chronic Lymphocytic Leukemia After Frontline Therapy
Enrollment Status: Completed
Publish Date: February 10, 2026
Intervention Type: Drug, Other
Study Drug: Ibrutinib
Study Phase: Phase 2
Phase I/II Trial of AT-101 in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed Symptomatic Multiple Myeloma
Phase I/II Trial of AT-101 in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed Symptomatic Multiple Myeloma
Enrollment Status: Completed
Publish Date: December 28, 2023
Intervention Type: Other, Drug
Study Drugs: Dexamethasone, Lenalidomide, R-(-)-Gossypol Acetic Acid
Study Phase: Phase 1
A Combined Phase 1/2 Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of TP-0903 in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)
A Combined Phase 1/2 Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of TP-0903 in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)
Enrollment Status: Terminated
Publish Date: November 09, 2023
Intervention Type: Drug, Combination product
Study Phase: Phase 1/Phase 2
Impact of Short Term Lenalidomide on Immune Response to Prevnar 13® in Individuals With Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Leukemia (SLL), and Monoclonal B Cell Lymphocytosis (MBL)
Impact of Short Term Lenalidomide on Immune Response to Prevnar 13® in Individuals With Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Leukemia (SLL), and Monoclonal B Cell Lymphocytosis (MBL)
Enrollment Status: Terminated
Publish Date: January 19, 2021
Intervention Type: Biological, Other, Drug
Study Phase: Phase 2
A Phase I/II Clinical Trial of Lenalidomide in Combination With AT-101 for the Treatment of Relapsed B-Cell Chronic Lymphocytic Leukemia (B-CLL)
A Phase I/II Clinical Trial of Lenalidomide in Combination With AT-101 for the Treatment of Relapsed B-Cell Chronic Lymphocytic Leukemia (B-CLL)
Enrollment Status: Terminated
Publish Date: June 16, 2020
Intervention Type: Other, Drug
Study Phase: Phase 1/Phase 2
Phase II Study of LCL161 Alone and in Combination With Cyclophosphamide in Patients With Relapsed or Refractory Multiple Myeloma
Phase II Study of LCL161 Alone and in Combination With Cyclophosphamide in Patients With Relapsed or Refractory Multiple Myeloma
Enrollment Status: Completed
Publish Date: September 10, 2019
Intervention Type: Other, Drug
Study Phase: Phase 2
View 7 Less Clinical Trials

153 Total Publications

Number needed to treat to avoid progression and death and cost analysis: zanubrutinib versus acalabrutinib in relapsed/refractory chronic lymphocytic leukemia.
Number needed to treat to avoid progression and death and cost analysis: zanubrutinib versus acalabrutinib in relapsed/refractory chronic lymphocytic leukemia.
Journal: Future oncology (London, England)
Published: January 31, 2026
Similar Doctors
Expertise in
24
conditions
Dr. Vivek K. Roy
Hematology
Expertise in
24
conditions
Dr. Vivek K. Roy
Hematology
Referral may be required

Mayo Clinic Hematology & Oncology

4500 San Pablo Rd S, 
Jacksonville, FL 
 (0.1 miles away)
904-953-7188
Experience:
47+ years
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Vivek Roy is a Hematologist practicing medicine in Jacksonville, Florida. He has been practicing medicine for over 47 years. Dr. Roy is highly rated in 24 conditions, according to our data. His clinical expertise encompasses Multiple Myeloma, Waldenstrom Macroglobulinemia, Non-Hodgkin Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Roy is currently accepting new patients.

Expertise in
21
conditions
Dr. Han W. Tun
Hematology
Expertise in
21
conditions
Dr. Han W. Tun
Hematology
Referral may be required

FL - Cancer

4500 San Pablo Rd S, 
Jacksonville, FL 
 (0.1 miles away)
904-914-7532
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Han Tun is a Hematologist practicing medicine in Jacksonville, Florida. Dr. Tun is highly rated in 21 conditions, according to our data. His clinical expertise encompasses Non-Hodgkin Lymphoma, B-Cell Lymphoma, Marginal Zone Lymphoma (MZL), Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Tun is currently accepting new patients.

Expertise in
35
conditions
Expertise in
35
conditions
Referral may be required

Mayo Clinic Hematology & Oncology

4500 San Pablo Rd S, 
Jacksonville, FL 
 (0.1 miles away)
904-953-7188
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Ernesto Ayala is a Hematologist practicing medicine in Jacksonville, Florida. Dr. Ayala is highly rated in 35 conditions, according to our data. His clinical expertise encompasses Non-Hodgkin Lymphoma, Graft Versus Host Disease (GvHD), Myelodysplastic Syndrome (MDS), Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Ayala is currently accepting new patients.

Frequently Asked Questions about Dr. Asher A. Chanan-Khan

How do I make an appointment with Dr. Asher A. Chanan-Khan?

You can book an appointment with Dr. Asher A. Chanan-Khan by calling their office at 904-953-2000. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Asher A. Chanan-Khan a top-rated expert for Chronic Lymphocytic Leukemia (CLL)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Asher A. Chanan-Khan is classified as an Elite expert for Chronic Lymphocytic Leukemia (CLL), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Asher A. Chanan-Khan specialize in?

While Dr. Asher A. Chanan-Khan is a Hematology, they have specific expertise in Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma, and Waldenstrom Macroglobulinemia. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Asher A. Chanan-Khan participate in research or clinical trials?

Yes. Dr. Asher A. Chanan-Khan has published 153 articles and abstracts on conditions like Chronic Lymphocytic Leukemia (CLL). You can view a list of Dr. Asher A. Chanan-Khan's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Asher A. Chanan-Khan accept my insurance?

Dr. Asher A. Chanan-Khan accepts most major insurance plans, including Blue Cross Blue Shield and UnitedHealthcare. We recommend calling the office directly at 904-953-2000 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Chanan-Khan's expertise for a condition
ConditionClose
View All 9 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile